IDEAYA reports Q4 2024 net loss of $130.3M; cash ~$1.1B, funds operations into at least 2028

IDEAYA Biosciences, Inc.

2024-FY EPS reported -$3.36 revenue$7,000,000

Cash, equivalents and marketable securities of ~$1.1B as of Dec 31, 2024, up from $632.6M in 2023.
Net loss for Q4 2024 was $130.3M vs $34.0M in Q4 2023; full-year net loss $274.5M vs $113.0M.
R&D expenses surged to $140.2M in Q4 2024 from $38.8M, driven by $75M upfront for IDE849 license from Hengrui.
Over 230 patients enrolled in darovasertib + crizotinib Phase 2/3 in 1L HLA-A2-negative MUM; median PFS readout by year-end 2025.
Announced three development candidates: IDE892 (PRMT5), IDE034 (B7H3/PTK7 ADC), IDE251 (KAT6/7); INDs targeted in 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.